Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)...(the European Union prior to the end of t...),Health

Date:12/11/2007

the European Union prior to the end of the year or at all, and any marketing approval, if granted, may have significant limitations on its use. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements.

These and other risks are described in detail in the Gilead's Annual Report on Form 10-K for the year ended December 31, 2006 and its Quarterly Reports on Form 10-Q for the first three quarters of 2007, filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update any such forward-looking statements.
Full U.S. prescribing information, including Boxed WARNINGS, for ATRIPLA is

available at http://www.atripla.com. Full U.S. prescribing information for SUSTIVA is available at http://www.bms.com. Full U.S. prescribing information for Truvada, Viread and Emtriva, including

Boxed WARNINGS, are available at http://www.gilead.com. EU Summary of Product Characteristics for Truvada, Viread, Emtriva, SUSTIVA and STOCRIN are available at http://www.emea.europa.eu/htms/human/epar/a.htm.
ATRIPLA is a registered trademark of Bristol-Myers Squibb & Gilead Sciences,

LLC. SUSTIVA is a registered trademark of Bristol-Myers Squibb Pharma Company.

STOCRIN is a registered trademark of Merck & Co., Inc. Truvada, Viread and Emtriva are all registered trademarks of Gilead Sciences,

Inc.

'/>"/>

SOURCE Bristol-Myers Squibb Company Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Bristol-Myers Squibb, New Jersey Childrens Hospital Launch Center for Immune System Disorders & Infectious Diseases Including HIV/AIDS
2. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
3. PARIs eFlow Included in Gileads NDA Submission for Aztreonam Lysine for Inhalation
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
7. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
8. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
11. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806